Activity content starts in:
Industry Webcast
VEOZAH™ (fezolinetant) For the Treatment of Moderate to Severe Vasomotor Symptoms Due to MenopauseIndustry Webcast Sponsored by Astellas Pharma US, Inc.; Not for CME/CE Credit
In this session, we will review an FDA-approved treatment for moderate to severe vasomotor symptoms due to menopause, including indication, mechanism of action, and clinical safety and efficacy.
CME/CE Information
0 Credits - Not for CME/CE Credit
Release Date: 1/14/2025
Expiration Date: 1/14/2025
Topics
Faculty
Faculty
Supporters and Partners
Industry Sponsor
Astellas Pharma US, Inc.
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.